{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-116642","form_type":"8-K","ticker":"VKTX","cik":"0001607678","company_name":"Viking Therapeutics, Inc.","filed_at":"2024-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.955023+00:00","generated_at":"2026-05-30T11:05:55.428577+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Viking Therapeutics Q3 net loss $24.9M; cash $930M; pipeline advances with VK2735 and VK2809","bullets":["Net loss of $24.9M ($0.22 per share) vs $22.5M loss in Q3 2023; R&D expense $22.8M.","Cash and equivalents of $930M at Sept 30, 2024, up from $362M at Dec 31, 2023.","End-of-Phase 2 meeting for subcutaneous VK2735 (obesity) planned for 4Q24; Phase 2 oral VK2735 trial expected to start 4Q24.","Positive Phase 2b VOYAGE results for VK2809 in NASH/MASH with fibrosis selected for oral presentation at AASLD Nov 19.","Positive Phase 1b results for VK0214 in X-ALD show reductions in very long-chain fatty acids and plasma lipids."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-116642","json":"https://secwatch.observer/filing/0000950170-24-116642.json","markdown":"https://secwatch.observer/filing/0000950170-24-116642.md","text":"https://secwatch.observer/filing/0000950170-24-116642.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024116642/0000950170-24-116642-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1607678/000095017024116642/vktx-20241023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:05:55.428577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}